ArticleArchives of osteoporosis2025
Joint position on vitamin D prescription in the adult Mexican population by AMMOM, AMEC, AMG, CMIM, CMO, CMR, CONAMEGER, FEMECOG, and FEMECOT.
Article in Archives of osteoporosis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitamin D deficiency remains a critical health concern linked to skeletal disorders such as osteoporosis, osteomalacia, and fractures. Recent evidence highlights the broader role of vitamin D in preventing chronic conditions, including autoimmune diseases, diabetes, and cardiovascular events. However, inconsistencies in clinical practice across Mexico and limited population-specific data necessitate standardized guidelines to address diagnostic and therapeutic challenges.
objectiveTo establish evidence-based recommendations for diagnosing and prescribing vitamin D supplements tailored to the Mexican adult population, reducing practice variability while promoting optimal health outcomes.
methodsA multidisciplinary panel comprising specialists from nine leading Mexican medical organizations conducted a consensus process using the Delphi methodology. The recommendations were developed using a combined approach, integrating extensive literature reviews with expert consensus to address areas where empirical evidence is limited. The process informed guidelines for vitamin D supplementation, measurement criteria, and therapeutic monitoring.
resultsKey recommendations include: Measuring 25(OH)D levels in adults with risk factors or conditions associated with hypovitaminosis D, avoiding routine screening in healthy individuals. Defining vitamin D deficiency as < 20 ng/mL, insufficiency as 20-29 ng/mL, and sufficiency as 30-100 ng/mL. Preferring cholecalciferol for supplementation, with calcifediol reserved for specific cases requiring rapid correction or compromised hepatic hydroxylation. Regularly monitor serum 25(OH)D concentrations to achieve and maintain levels between 30 and 60 ng/mL, ensuring safety and therapeutic efficacy.
conclusionThis joint position provides a comprehensive framework for managing hypovitaminosis D in Mexican adults. The recommendations aim to harmonize clinical practices, improve patient outcomes, and inform public health strategies for equitable resource allocation. Ongoing evaluation and stakeholder feedback will ensure adaptability and relevance as new evidence emerges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.